A microscopic image of a bioactive scaffold with bundles of nanoscale filaments in pink and hyaluronic acid molecules in purple.

Inside the 3D structure of the novel biomaterial, bundles of nanoscale filaments (pink) bind hyaluronic acid molecules (purple) and TGFβ-1 to stimulate stem-like cells to migrate into the structure and generate new cartilage.

Credit: Samuel Stupp Laboratory/Northwestern University

Regenerating cartilage with a biomaterial that acts like a drug

Using a sheep model, researchers developed an injectable biomaterial that interacts with nearby cells and recruits them to make new cartilage.
Allison Whitten
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00

Without cartilage — a pliable, supportive tissue found throughout the body — bones would rub up against one another at joints, causing limited movement and pain. Unfortunately, this is what happens when adults lose cartilage, since humans lose the ability to regenerate cartilage after age 18. “If there is an injury or if there is degeneration as a result of a special condition like osteoarthritis or something else, the tissue is unable to regrow,” said Samuel Stupp, a materials scientist at Northwestern University.

To fill in missing cartilage, Stupp’s team has been pioneering the development of new biomaterials that mimic the structure of the extracellular matrix (ECM) — with the goal to create a scaffold that is both biologically active and compatible with real tissue to promote regeneration. In a recent study, they designed a slurry-like material with nanoscale filaments that send signals inviting stem-like cells to migrate into it and make new cartilage (1). The nanoscale filaments are made out of peptide amphiphile molecules that self-assemble into bundles, where they bind hyaluronic acid molecules and transforming growth factor β-1 (TGFβ-1) that signals to nearby cells. Once it’s injected and comes into contact with calcium ions, the material transforms into a rubbery 3D structure where new cartilage grows to fill it in — and then the biomaterial disappears entirely. “The material is completely biodegradable,” said Stupp. “It doesn't leave any trace.”

By injecting the new biomaterial into sheep (a large-animal model that closely models human joints), the research team found that their scaffold initiated regeneration of the articular cartilage that covers and protects the ends of bones. “We were pleasantly surprised that it worked in sheep,” said Stupp, adding that they verified that the newly regenerated cartilage was comprised of the expected biopolymers found in normal cartilage ECM.

Now, Stupp’s team hopes to move their bioactive scaffold closer to patients. First, they plan to tweak its chemistry in ways that will make it easier to manufacture on a large scale for hospitals. “We are hoping to bring it to the clinic, optimize it, make sure that it is the best possible product, and then get permission from the FDA for the first clinical trial,” said Stupp.

Stupp added that unlike most prior interventions to repair joints, he believes that the Food and Drug Administration (FDA) should evaluate the scaffold as a combination product that is part device and part drug. “In this case, the material actually has molecules that interact directly with cells by design. So, there's a communication with cells, which is the way all drugs operate.”

Reference

  1. Lewis, J.A. et al. A bioactive supramolecular and covalent polymer scaffold for cartilage repair in a sheep model. Proc Natl Acad Sci USA  121, e2405454121 (2024).

About the Author

  • Allison Whitten
    Allison Whitten joined Drug Discovery News as an assistant editor in 2023. She earned her PhD from Vanderbilt University in 2018, and has written for WIRED, Discover Magazine, Quanta Magazine, and more.

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue